|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 266.30 CHF | -0.22% |
|
+1.29% | +4.42% |
| Jan. 20 | ROCHE HOLDINGS AG : Gets a Sell rating from JP Morgan | ZD |
| Jan. 16 | BioXcel Therapeutics, Inc. Appoints Rajiv Patni to the Board | CI |
| Capitalization | 215B 236B 227B 192B 339B 20,383B 378B 2,608B 966B 8,409B 887B 868B 36,805B | P/E ratio 2024 * |
16.1x | P/E ratio 2025 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise value | 230B 254B 244B 206B 363B 21,880B 405B 2,799B 1,037B 9,027B 952B 932B 39,509B | EV / Sales 2024 * |
3.79x | EV / Sales 2025 * | 3.47x |
| Free-Float |
88.86% | Yield 2024 * |
3.69% | Yield 2025 * | 3.79% |
More valuation ratios
* Estimated data
More news
Last Transcript: Roche Holding AG
More recommendations
More press releases
More news
| 1 day | +0.57% | ||
| 1 week | +0.76% | ||
| Current month | +4.46% | ||
| 1 month | +7.88% | ||
| 3 months | -2.34% | ||
| 6 months | -4.10% | ||
| Current year | +4.46% |
1 week
261.60
268.80
1 month
246.70272.80
Current year
254.10272.80
1 year
212.90288.20
3 years
212.90404.20
5 years
212.90404.20
10 years
206.35404.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2023-03-14 | |
Alan Hippe
DFI | Director of Finance/CFO | 58 | 2011-06-05 |
Levi Garraway
CTO | Chief Tech/Sci/R&D Officer | 57 | 2022-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 66 | 1995-12-31 |
Severin Schwan
CHM | Chairman | 58 | 2023-03-14 |
| Director/Board Member | 72 | 2015-03-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 30 M€ | +1.14% | - | |
| 4.67% | 0 M€ | -.--% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| +1.51% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.25% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -0.66% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.21% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 60.84B 67.01B 64.44B 54.48B 95.96B 5,777B 107B 739B 274B 2,383B 251B 246B 10,432B | 64.65B 71.21B 68.48B 57.9B 102B 6,139B 114B 785B 291B 2,533B 267B 262B 11,086B |
| Net income | 13.09B 14.42B 13.87B 11.72B 20.65B 1,243B 23.03B 159B 58.94B 513B 54.08B 52.96B 2,245B | 15.28B 16.83B 16.18B 13.68B 24.1B 1,451B 26.87B 186B 68.78B 599B 63.12B 61.81B 2,620B |
| Net Debt | 15.77B 17.37B 16.7B 14.12B 24.87B 1,497B 27.73B 192B 70.98B 618B 65.14B 63.79B 2,703B | 9.89B 10.9B 10.48B 8.86B 15.6B 940B 17.4B 120B 44.54B 388B 40.87B 40.03B 1,696B |
More financial data
* Estimated data
Employees
103,605
Sector
Pharmaceuticals
Calendar
2025-01-30
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-21 | 266.60 CHF | -0.11% | 31,189 |
| 25-01-20 | 266.90 CHF | +0.57% | 816,180 |
| 25-01-17 | 265.40 CHF | -1.19% | 1,326,291 |
| 25-01-16 | 268.60 CHF | +1.02% | 831,690 |
| 25-01-15 | 265.90 CHF | +0.95% | 1,044,788 |
Delayed Quote Swiss Exchange, January 20, 2025 at 11:30 am EST
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
266.90CHF
Average target price
303.47CHF
Spread / Average Target
+13.70%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
